Abstract

Unit dosage forms, devices, and kits for topical delivery of topical immunosensitizers are provided. These include dermal patches, glass swabs, and kits containing a dermal patch and a glass swab. Among other advantages, the unit dosage forms, devices, and kits presented herein deliver a more consistent and controlled volume of drug solution, prevent underdosing and overdosing, prevent or discourage repeat dosing, and provide a more consistent skin area to which the drug solution is applied.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61F 13/40 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the bodySupporting or fastening means thereforTampon applicators having means integral therewith for supplying media to the absorbent material, e.g. contained in a rupturable reservoir
• A61F 13/00 - Bandages or dressingsAbsorbent pads

Abstract

Unit dosage forms, devices, and kits for topical delivery of topical immunosensitizers are provided. These include dermal patches, glass swabs, and kits containing a dermal patch and a glass swab. Among other advantages, the unit dosage forms, devices, and kits presented herein deliver a more consistent and controlled volume of drug solution, prevent underdosing and overdosing, prevent or discourage repeat dosing, and provide a more consistent skin area to which the drug solution is applied.

IPC Classes  ?

• A61M 35/00 - Devices for applying media, e.g. remedies, on the human body
• A61J 1/06 - Ampoules or cartridges
• A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/70 - Web, sheet or filament bases
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Abstract

A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site other than at the site of an HSV lesion to induce a DTH response during one or more outbreaks of the HSV infection. The method reduces the number of HSV outbreaks in persons experiencing outbreaks.

IPC Classes  ?

• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/04 - Nitro compounds
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 35/763 - Herpes virus
• A61K 39/12 - Viral antigens
• A61K 39/165 - Mumps or measles virus
• C07K 14/035 - Herpes simplex virus I or II
• G01N 33/571 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea, herpes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A method is presented for treating viral and fungal infections by applying a topical immunosensitizer to the skin of a person infected with a virus or fungus and in need of treatment for the viral or fungal infection. Methods of improving anti- viral and anti-fungal immunity are also presented, and methods of increasing PBMC interferon gamma expression in response to a viral or fungal immune stimulus.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/10 - Antimycotics
• A61P 31/12 - Antivirals
• A61P 37/02 - Immunomodulators

Abstract

A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.

IPC Classes  ?

• A61K 31/12 - Ketones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/08 - Ethers or acetals acyclic, e.g. paraformaldehyde
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/04 - Nitro compounds
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/165 - Mumps or measles virus
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.

IPC Classes  ?

• A61K 31/04 - Nitro compounds
• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61K 39/165 - Mumps or measles virus
• A61K 39/12 - Viral antigens
• A61K 35/763 - Herpes virus
• C07K 14/035 - Herpes simplex virus I or II
• G01N 33/571 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea, herpes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.

IPC Classes  ?

• A61K 35/763 - Herpes virus
• A61K 39/165 - Mumps or measles virus
• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C07K 14/035 - Herpes simplex virus I or II
• C12N 15/38 - Herpetoviridae, e.g. herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, pseudorabies virus
• G01N 33/571 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea, herpes

Abstract

A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.

IPC Classes  ?

• A61K 35/763 - Herpes virus
• A61K 39/165 - Mumps or measles virus
• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C07K 14/035 - Herpes simplex virus I or II
• C12N 15/38 - Herpetoviridae, e.g. herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, pseudorabies virus
• G01N 33/571 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea, herpes